Adaptive Biotechnologies ADPT Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Revenue by Business | ||||||
| Immune Medicine Business | $59.7M+81.4% | $64.64M+93.4% | $62.16M+51.1% | $33.94M-25.3% | $32.9M-45.7% | |
| Mrd Business | $235.71M+50.5% | $212.33M+45.9% | $190.6M+40.0% | $171.28M+38.9% | $156.62M+37.5% | |
| Adjusted Ebitda by Business | ||||||
| Mrd Business | $31.44M+212% | $15.19M+137% | -$1.79M+96.6% | -$14.87M+78.1% | -$28.08M+64.8% | |
| Research And Development Expense by Business | ||||||
| Immune Medicine Business | $55.31M-2.8% | $55.86M-6.5% | $56.96M-15.1% | $57.21M-20.1% | $56.88M-24.9% | |
| Mrd Business | $35.09M-5.1% | $35.03M-14.0% | $35.19M-17.6% | $35.43M-19.6% | $36.98M-17.0% | |
| Revenue by Product | ||||||
| Collaboration Revenue | $37.68M+205% | $41.28M+207% | $44.78M+151% | $14.55M-35.0% | $12.36M-67.6% | |
| Regulatory Milestone Revenue | $24M+92.0% | $19.5M+56.0% | $16.5M— | $15M— | $12.5M— | |
| Service And Licensing Revenue | $21.3M+2.3% | $23.36M+16.9% | $22.51M+6.1% | $21.67M-3.6% | $20.82M-12.2% | |
| Service | $211.71M+46.9% | $192.83M+45.0% | $174.1M+40.8% | $156.28M+34.9% | $144.12M+31.7% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Adaptive Biotechnologies break its business down?
- Adaptive Biotechnologies (ADPT) reports revenue by business across 2 parts — Immune Medicine Business and Mrd Business. Each is extracted from the segment footnotes and tracked over time.
- Where does Adaptive Biotechnologies's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Adaptive Biotechnologies's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
